Foundation Medicine's Revenues Double as it Readies Hematological Cancer Panel | GenomeWeb

This story was originally published Nov. 8.

The newly-public Foundation Medicine saw its quarterly revenues more than double to $8.2 million in the third quarter compared to $3 million in the previous year's third quarter, and it's finalizing its second next-generation sequencing-based cancer panel for hematological malignancies, the company said this week.

"We see FoundationOne as our starting point, not the finish line," President and CEO Michael Pellini said during a conference call discussing the company's earnings.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.